JNCCN 360 - Advanced Skin Cancers - News

Advertisement

Advertisement

News

ASTRO 2026: Nivolumab Plus Ipilimumab Shows Durable Responses in Advanced Merkel Cell Carcinoma

FDA Approves Topical Photodynamic Therapy for Superficial BCC

AI Epigenomic Model May Flag CSCC Risk Among Those With Hidradenitis Suppurativa

FDA Approves Vusolimogene Oderparepvec and Nivolumab for Advanced Melanoma

ctDNA vs Antibody Testing for the Detection of Recurrent MCC

PIVOTAL Trial Update: Neoadjuvant Intralesional Daromun in Resectable Locally Advanced Melanoma

PIVOTAL Trial Update: Neoadjuvant Intralesional Daromun in Resectable Locally Advanced Melanoma

ASCO 2026: RAMPART Trial Investigates Response-Adapted Cemiplimab Plus Radiotherapy in Unresectable CSCC

ASCO 2026: RAMPART Trial Investigates Response-Adapted Cemiplimab Plus Radiotherapy in Unresectable CSCC

ASCO 2026: Adjuvant Avelumab Reduced Relapse Risk in Stage III Merkel Cell Carcinoma

ASCO 2026: ATR Inhibition Plus Avelumab May Benefit Patients With ICI-Refractory Merkel Cell Carcinoma

FDA Expands Sunscreen Options for the First Time in 20 Years

AACR 2026: Alopecia Areata Linked to Lower Nonmelanoma Skin Cancer Risk

AACR 2026: Final Phase III Data Support Nivolumab Plus Ipilimumab for Patients With Metastatic Melanoma

Copyright © 2026 National Comprehensive Cancer Network, All Rights Reserved